Mitsubishi Chemical Group (4188) Q4 2026 earnings summary

Executive summary

• FY 2025 saw core operating income down 2% to JPY 225 billion, with operating income plunging 79% to JPY 30.1 billion and profit attributable to owners down 74% to JPY 11.8 billion, mainly due to non-recurring items and restructuring costs.

• Major structural reforms included withdrawal from coke and carbon materials, ethylene restructuring, dissolution of overseas MMA JVs, and voluntary retirement programs.

• Specialty Materials performed steadily, with core operating income rising, while MMA and Materials & Polymers faced a sluggish environment and asset impairments.

• The transfer of Mitsubishi Tanabe Pharma was completed, with its operations now classified as discontinued.

• Management implemented stricter oversight, including executive compensation cuts in response to missed operational discipline.

Financial highlights

• FY 2025 sales revenue was JPY 3,704 billion, down 6% year-on-year, with core operating income at JPY 225 billion and net income attributable to owners at JPY 11.8 billion.

• Operating income fell 79% to JPY 30.1 billion; net income from discontinued operations was JPY 94.8 billion, mainly from the Mitsubishi Tanabe Pharma transfer.

• Free cash flow increased to JPY 560.8 billion, up from JPY 277.4 billion in the prior year, driven by asset sales.

• Special items totaled negative JPY 194.9 billion, worsening by JPY 107.7 billion year-on-year.

• Cash and cash equivalents at year-end rose to JPY 527.1 billion, up JPY 201.0 billion.

Outlook and guidance

• FY 2026 core operating income is forecast at JPY 305 billion, up 36% year-on-year, with net income attributable to owners expected to reach JPY 127 billion.

• FY 2027 guidance projects sales revenue of JPY 3,800 billion, core operating income of JPY 305 billion, and net income attributable to owners of JPY 127 billion.

• Dividend forecast for FY 2026 is JPY 32 per share, unchanged from FY 2025.

• Forecasts do not include potential impacts from Middle East geopolitical risks; a prolonged crisis could reduce core operating income by JPY 18 billion.

• Growth is expected from Specialty Materials, with recovery in MMA and continued cost reductions.